Cargando…

EGFR Signaling in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Therapeutic Opportunities

Detalles Bibliográficos
Autor principal:	La Monica, Silvia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025122/ https://www.ncbi.nlm.nih.gov/pubmed/35456023 http://dx.doi.org/10.3390/cells11081344

Ejemplares similares

Cancer Immunology: From Molecular Mechanisms to Therapeutic Opportunities
por: Mattei, Fabrizio, et al.
Publicado: (2022)

Treatment strategy of EGFR-mutated non-small cell lung cancer
por: Tanaka, Fumihiro, et al.
Publicado: (2022)

Molecular Biology of Ovarian Cancer: From Mechanisms of Intraperitoneal Metastasis to Therapeutic Opportunities
por: Książek, Krzysztof
Publicado: (2021)

Muscle Homeostasis and Regeneration: From Molecular Mechanisms to Therapeutic Opportunities
por: Musarò, Antonio
Publicado: (2020)

Oncogenic Signalling of Growth Factor Receptors in Cancer: Mechanisms and Therapeutic Opportunities
por: Dricu, Anica
Publicado: (2022)

Critical points in the management of EGFR-mutated non-small cell lung cancer
por: Casaluce, Francesca, et al.
Publicado: (2022)

EGFR and non-small cell lung cancer: implications for surgical practice
por: Varela, Gonzalo, et al.
Publicado: (2020)

Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
por: Tanzawa, Shigeru, et al.
Publicado: (2019)

Complex EGFR mutations in non-small cell lung cancer: a distinct entity?
por: Bieńkowski, Michał, et al.
Publicado: (2022)

Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer
por: Eltayeb, Kamal, et al.
Publicado: (2022)

The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies
por: Laface, Carmelo, et al.
Publicado: (2023)

Postoperative management for non-small cell lung cancer harboring EGFR mutations
por: Tanaka, Fumihiro, et al.
Publicado: (2020)

Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer
por: Shepherd, Annemarie F., et al.
Publicado: (2020)

Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold!
por: Fiorelli, Alfonso, et al.
Publicado: (2020)

Ferroptosis in Lung Cancer: From Molecular Mechanisms to Prognostic and Therapeutic Opportunities
por: Tabnak, Peyman, et al.
Publicado: (2021)

Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities
por: Rosell, Rafael, et al.
Publicado: (2021)

Acquired BRAF gene fusions in Osimertinib resistant EGFR-mutant non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies
por: Koulouris, Andreas, et al.
Publicado: (2022)

Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring
por: Reita, Damien, et al.
Publicado: (2021)

Obesity paradox and lung cancer, metformin-based therapeutic opportunity?
por: Barrios-Bernal, Pedro, et al.
Publicado: (2023)

Making the Most of Complexity to Create Opportunities: Comprehensive Genomic Profiling and Molecular Tumor Board for Patients with Non-Small Cell Lung Cancer (NSCLC)
por: Fumagalli, Caterina, et al.
Publicado: (2021)

Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancer—ready for prime time?
por: Arulananda, Surein, et al.
Publicado: (2020)

Molecular mechanism and clinical outcome of non-small cell lung cancer patients with high BRAF expression
por: Uehara, Yuji
Publicado: (2023)

Targeting HSF1 as a Therapeutic Strategy for Multiple Mechanisms of EGFR Inhibitor Resistance in EGFR Mutant Non-Small-Cell Lung Cancer
por: Lee, Sangah, et al.
Publicado: (2021)

Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?
por: Lemmon, Christopher, et al.
Publicado: (2020)

Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
por: Kanemura, Hiroaki, et al.
Publicado: (2020)

Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
por: Patel, Shruti R., et al.
Publicado: (2023)

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
por: Leonetti, Alessandro, et al.
Publicado: (2019)

The impact of age and performance status on the efficacy of osimertinib in patients with EGFR T790M-positive non-small cell lung cancer
por: Gil, Hyun-Il, et al.
Publicado: (2020)

Plasma-derived immune-related factors as biomarkers of osimertinib resistance in EGFR-mutant non-small cell lung cancer patients
por: Hydbring, Per
Publicado: (2023)

Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer
por: Lee, Chaelin, et al.
Publicado: (2022)

Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities
por: Zubair, Tanzida, et al.
Publicado: (2023)

Molecular Predictors of EGFR-TKI Sensitivity in Advanced Non–small Cell Lung Cancer
por: Zhang, Xiaozhu, et al.
Publicado: (2008)

Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer
por: Farnsworth, Dylan A., et al.
Publicado: (2021)

EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic?
por: Steuer, Conor E., et al.
Publicado: (2020)

Future prospects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and surgery for non-small cell lung cancer
por: Nagano, Tatsuya, et al.
Publicado: (2022)

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
por: Fu, Kai, et al.
Publicado: (2022)

Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer
por: Park, Silvia, et al.
Publicado: (2015)

Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer
por: Nishihara, Shigetoshi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0j5hq4k91cussq1br41upkj89j